🇺🇸 FDA
Pipeline program

KEYTRUDA 25 mg/mL concentrate for solution for infusion, BAY 734506

TRIO041

Phase 3 small_molecule active

Quick answer

KEYTRUDA 25 mg/mL concentrate for solution for infusion, BAY 734506 for Intermediate-stage hepatocellular carcinoma with beyond up-to-7 criteria. is a Phase 3 program (small_molecule) at Ology Bioservices Ireland LTD with 1 ClinicalTrials.gov record(s).

Program details

Company
Ology Bioservices Ireland LTD
Indication
Intermediate-stage hepatocellular carcinoma with beyond up-to-7 criteria.
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials